Investment Rating - The investment rating for JD Health (6618.HK) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on performance metrics and growth potential [1][12]. Core Viewpoints - JD Health reported a revenue of approximately 35.29 billion yuan for H1 2025, representing a year-on-year increase of 24.5%. The pre-tax profit was 2.864 billion yuan, up 17.4% year-on-year, and the net profit attributable to shareholders was about 2.591 billion yuan, reflecting a 27.4% increase [2][3]. - The growth in revenue is driven by an increase in active user numbers, improved penetration rates, and an expansion of product categories. The active user count exceeded 200 million, with an average of over 500,000 daily consultations in H1 2025 [3][4]. - The company continues to expand its product launch lineup, including innovative drugs and non-pharmaceutical products, which are expected to enhance sales and user engagement [3][4]. Financial Summary - For the fiscal years 2024A to 2027E, total revenue is projected to grow from 58.16 billion yuan in 2024 to 93.737 billion yuan in 2027, with year-on-year growth rates of 9%, 21%, 15%, and 16% respectively [5][6]. - The pre-tax profit is expected to increase from 4.797 billion yuan in 2024 to 7.13 billion yuan in 2027, with corresponding growth rates of 78.13%, 14.93%, 12.10%, and 15.37% [5][6]. - The gross margin is anticipated to improve from 22.88% in 2024 to 25.18% in 2027, indicating enhanced profitability [5][6]. User Engagement and AI Integration - The company has integrated AI into its healthcare services, with the "AI Jingyi" platform serving over 50 million users by June 30, 2025. This includes various AI-driven services for patients and healthcare professionals [3][4]. - JD Health is also enhancing its specialized medical capabilities, focusing on areas such as dermatology, mental health, and traditional Chinese medicine, which have collectively served over 20 million patients [4].

Group 1: Financial Performance - JD Health reported total revenue of RMB 35.3 billion for the first half of 2025, representing a year-on-year growth of 24.5%, indicating accelerated growth and strong financial performance [2] - The number of annual active users exceeded 200 million as of June 30, 2025, which significantly contributed to the growth in sales of pharmaceutical and health products [2] Group 2: Market Trends - The internet healthcare sector has experienced unprecedented growth due to the pandemic, with a shift in patient demand towards online services, although there are concerns about the limitations of internet healthcare as user expectations evolve [2][8] - A survey indicated that 83.72% of consumers have a habit of keeping medications at home, with 40.46% of respondents purchasing medications online more than 50% of the time [3] Group 3: Competitive Advantages - JD Health leverages its supply chain advantages to create a strong competitive barrier, enhancing user perception of speed, comprehensiveness, and quality [5] - The integration of instant retail services, such as "JD Seconds," allows for delivery within 9 minutes, significantly improving customer experience [5][6] Group 4: Service Innovations - JD Health has introduced "JD Home Quick Testing" services, providing at-home testing for various conditions, which addresses the needs of patients seeking to avoid hospital visits [10][12] - The company has expanded its nursing services to include 64 items across seven categories, enhancing its service offerings for patients requiring professional care [10] Group 5: Technology Integration - JD Health has developed AI diagnostic tools that improve the efficiency and accuracy of online consultations, with the AI diagnostic assistant achieving a 99.5% accuracy rate in triage [18][19] - The launch of the "JD Zuo Yi" model product aims to optimize various healthcare processes, enhancing user experience and operational efficiency for healthcare providers [19]

Group 1 - The event "Doctors Have Light - 2025 China Physician Day Special Event" was held by JD Health to honor medical professionals and promote respect for healthcare workers [1] - The event recognized 40 outstanding doctors from across the country and highlighted their contributions to internet healthcare, enhancing service accessibility through innovative technologies [1][2] - The campaign "Thank You, My Treasure Doctor" launched by JD Health, Health China, and Sina Weibo engaged over 1.4 million people, with more than 150,000 participants sharing over 260,000 stories of gratitude towards doctors [1] Group 2 - JD Internet Hospital reported an average of over 500,000 online consultations per day as of June 30, further solidifying its position as the "first entry point for online diagnosis and treatment" [2] - The hospital has established a five-specialty system focusing on dermatology, mental health, traditional Chinese medicine, oncology, and andrology, enhancing the quality and efficiency of online medical services [2] - A total of 4,408 doctors were awarded the "Five-Year Big Shot Doctor" honor, recognizing their contributions and commitment to the internet healthcare sector [3] Group 3 - The event served to strengthen communication and understanding between doctors and patients, fostering a positive social atmosphere that respects healthcare professionals [3] - JD Health aims to continue innovating healthcare service models, providing better platforms for doctors and more accessible services for patients, contributing to the implementation of the Healthy China strategy [3]

Group 1 - The event "Doctors Shine - 2025 China Physician Day Special Event" was hosted by JD Health to honor medical professionals and promote respect for healthcare workers [1] - The event recognized 40 outstanding doctors from across the country and highlighted their contributions to internet healthcare, enhancing service accessibility through innovative technologies [1][2] - A story collection campaign titled "Thank You, My Treasure Doctor" was launched, engaging over 1.4 million people and collecting more than 260,000 patient-doctor stories [1] Group 2 - JD Internet Hospital reported an average of over 500,000 online consultations per day as of June 30, further solidifying its position as the "first entry point for online diagnosis and treatment" [2] - The hospital has established a five-specialty system focusing on dermatology, mental health, traditional Chinese medicine, oncology, and urology, enhancing the quality and efficiency of online medical services [2] - A total of 4,408 doctors were awarded the "Five-Year Veteran Doctor" honor, recognizing their commitment and contributions to the internet healthcare sector [3] Group 3 - The event served to enhance communication and understanding between doctors and patients, fostering a positive social atmosphere that respects healthcare professionals [3] - JD Health aims to continue innovating healthcare service models, providing better platforms for doctors and more accessible services for patients, contributing to the implementation of the Healthy China strategy [3]

中金认为，京东健康1H25业绩超市场预期，分业务板块看，公司实现产品收入293.3亿元 (+22.7%YoY)，服务收入59.6亿元(+34.4%YoY)，整体表现强劲。该行测算2Q25单季度实现收入186.5亿 元(+23.7%YoY)，预计京东集团主站在1H期间进行的即时零售投流活动或间接为京东健康带来流量导引 获益；截至1H25末，公司过去十二个月(LTM)活跃用户数超2亿，创历史新高。同时，该行预计药品品 类在1H期间或实现高于整体收入端的增速，仍为核心驱动品类。此外，该行认为公司虽坚定AI及线下 零售体系的业务布局，但反内卷基调之下整体投入或有所控制，对全年基本面亦带来正向贡献。 本文源自：智通财经网 京东健康(06618)再涨超10%，绩后累计涨超20%。截至发稿，涨9.71%，报67.2港元，成交额10.73亿港 元。 消息面上，近日，京东健康公布上半年业绩。华泰证券指出，京东健康今年上半年总收入352.9亿元， 按年增24.5%，高于市场一致预期的增长20.2%。该行认为，京东健康有望持续受益于京东主站的快速 流量增长(据QuestMobile，2025年5月至7月，京东APP的日活跃用户(D ...

Core Insights - JD Health (06618) reported a revenue of 35.29 billion RMB in the first half of the year, representing a year-on-year growth of 24.5% [1] - The non-IFRS net profit reached 3.57 billion RMB, up 35% year-on-year, with a non-IFRS net profit margin of 10.1%, an increase of 0.8 percentage points, exceeding market expectations [1] - The strong performance is attributed to the robust growth in the pharmaceutical category and favorable collaborations with pharmaceutical companies [1] Financial Projections - The company has raised its net profit forecasts for 2025 and 2026 by 30% and 21%, respectively, to 4.51 billion RMB and 5.28 billion RMB [1] - The overall valuation of the sector has recently increased, leading to a maintained "outperform" rating for the company [1] Market Performance - JD Health's stock price performed strongly in the first half of the year, benefiting from immunity to external demand factors such as tariffs and a stable competitive landscape in the domestic market [1] - Both quarters of the first half exceeded market expectations, and the overall rise in Hong Kong stock valuations contributed to the company's strong performance as a weighted stock in multiple indices [1] Valuation and Growth Potential - Despite the current valuation being relatively high compared to recent years, the company's strong growth potential provides fundamental support [1] - The recent positive sentiment in the Hong Kong stock sector suggests that the company may experience a valuation uplift in line with market trends [1]

Core Viewpoint - Macquarie's report indicates that JD Health (06618) has achieved a 25% year-on-year revenue growth to RMB 35.3 billion, with adjusted operating profit rising by 57%, exceeding both the bank's and market expectations by 8% and 11% respectively [1] Group 1: Financial Performance - JD Health's total revenue increased by 25% year-on-year to RMB 35.3 billion [1] - Adjusted operating profit rose by 57%, surpassing market expectations [1] - The bank has raised its profit forecasts for 2025 and 2026 by 30% and 24% respectively based on the first half performance and supply chain advantages [1] Group 2: Strategic Insights - The company is benefiting from a clear "pharmaceutical and health" closed-loop ecological strategy and channel expansion, marking a development turning point [1] - JD Health's core supply chain competitiveness is expected to translate into stronger pricing power, further driving margin expansion [1] Group 3: Market Position and Future Outlook - JD Group (09618) is actively promoting its food delivery business, which is contributing to user traffic growth for JD Health [1] - The bank anticipates that sales and marketing cost savings will continue into the second half of the year [1] - The forecast for the second half of 2025 indicates a 22% year-on-year revenue growth, with an expected 30 basis points expansion in adjusted net profit margin for the full year [1]

另外，母公司京东集团(09618) 持续推动食品外卖业务，为京东健康带来用户流量增长，该行料销售及 推广费用节省将延续至下半年;现预测2025年下半年收入同比增长22%，全年经调整净利润率有望扩张 30个基点。 智通财经APP获悉，麦格里发布研报称，京东健康(06618)总收入同比增长25%至353亿元人民币，经调 整经营利润升57%，较该行及市场预期高8%及11%。该行认为公司凭借清晰的"医药与健康"闭环生态战 略，以及渠道扩张布局，已迎来发展拐点;其供应链核心竞争力有望转化为更强的定价能力，进一步推 动利润率扩张。基于上半年业绩及供应链优势，该行将2025及26年盈利预测分别上调30%及24%，评级 升至"跑赢大市"。 ...

Core Viewpoint - JD Health's strong performance in the first half of the year exceeded market expectations, driven by significant revenue growth and user engagement [1][2] Group 1: Financial Performance - JD Health reported total revenue of 35.29 billion yuan in the first half of the year, representing a year-on-year increase of 24.5%, surpassing the market consensus growth of 20.2% [1] - The company achieved product revenue of 29.33 billion yuan (+22.7% YoY) and service revenue of 5.96 billion yuan (+34.4% YoY) [2] - In Q2, JD Health's revenue reached 18.65 billion yuan, reflecting a year-on-year growth of 23.7% [2] Group 2: User Engagement and Growth - As of the end of the first half of the year, JD Health had over 200 million active users in the past twelve months, marking a historical high [2] - The daily active users (DAU) of the JD app grew by 44.8%, 33.4%, and 46.4% year-on-year from May to July 2025, indicating strong traffic growth [1] Group 3: Strategic Initiatives - JD Health is expected to benefit from the rapid traffic growth of JD's main platform and increased advertising demand from upstream partners [1] - The company's ongoing investment in medical AI is seen as a key driver for improving operational efficiency and enhancing user experience [1]

智通财经APP获悉，京东健康(06618)再涨超10%，绩后累计涨超20%。截至发稿，涨9.71%，报67.2港 元，成交额10.73亿港元。 中金认为，京东健康1H25业绩超市场预期，分业务板块看，公司实现产品收入293.3亿元 (+22.7%YoY)，服务收入59.6亿元(+34.4%YoY)，整体表现强劲。该行测算2Q25单季度实现收入186.5亿 元(+23.7%YoY)，预计京东集团主站在1H期间进行的即时零售投流活动或间接为京东健康带来流量导引 获益；截至1H25末，公司过去十二个月(LTM)活跃用户数超2亿，创历史新高。同时，该行预计药品品 类在1H期间或实现高于整体收入端的增速，仍为核心驱动品类。此外，该行认为公司虽坚定AI及线下 零售体系的业务布局，但反内卷基调之下整体投入或有所控制，对全年基本面亦带来正向贡献。 消息面上，近日，京东健康公布上半年业绩。华泰证券指出，京东健康今年上半年总收入352.9亿元， 按年增24.5%，高于市场一致预期的增长20.2%。该行认为，京东健康有望持续受益于京东主站的快速 流量增长(据QuestMobile，2025年5月至7月，京东APP的日活跃用户(DA ...